Artificial Intelligence

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

The US DSCSA requires digital drug traceability to ensure patient safety, but supply chains face data errors; deploying AI adds an intelligent compliance layer to automate process tracking and protect drug access.

BMS will deploy enterprise AI across functions to streamline workflows, structure field insights, and improve HCP engagement and execution.

Ben Sharples, LogiPharma event director, examines how life sciences organizations are adapting to AI in the supply chain, with expert testimony from LogiPharma partners.

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain transformation.

Rahul Shah and Mack MacKenzie explain how to unlock the ROI that rules-based systems have left on the table.

Brightseed debuts a clinically validated AI platform to integrate life sciences innovation from discovery to commercialization

The AI-native operating system targets complex workflows, automating claims and communications to reclaim logistics teams' time.

By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to move from reactive firefighting to proactive resilience—supporting faster responses, smarter tradeoffs, and more reliable patient care delivery.

Traditional market access practices are being transformed by an increasingly rocky landscape of rebate, discount, and direct-distribution practices, but artificial intelligence may clear the pathways to profitability.

As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.

AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

This guide outlines a proven framework, spanning process, people, and platform, to help healthcare innovators scale AI with compliance, collaboration, and clinical impact in mind.

How next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, faster issue resolution, and greater operational efficiency across the global drug distribution network.

In the second part of her Pharma Commerce video interview, Linda Malek, JD, partner at Crowell & Moring, notes that by bringing regulators and innovators together, regulatory sandboxes could help US healthcare organizations test and refine AI tools responsibly, which allows oversight agencies to keep pace with rapid technological change.

Christy Christian, senior industry principal with Kinaxis, and Hari Kiran Chereddi, CEO of HRV Pharma, explain why AI’s reliability depends on product stability, how human judgment still matters, and how a digital, AI-validated manufacturing backbone is accelerating regulatory reviews, strengthening supplier management, and transforming global production readiness.

Bayer’s Luiz Barberini highlights how artificial intelligence is transforming supply chain operations, while emphasizing the irreplaceable value of trust, transparency, and human relationships.

In the second part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, explains how wide regional price gaps and lack of visibility in global distribution create openings for counterfeit sellers—with many now specializing in categories like oncology—who exploit platforms such as Facebook and Instagram to market fake drugs.

In the first part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, warns that counterfeiters are using generative AI to clone pharmaceutical packaging, build convincing fake websites, and manipulate search results. rapidly outpacing enforcement efforts and putting patients at serious risk.

In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes to what extent he believes artificial intelligence should be used at this particular point in time.

Ways to address limitations while also enhancing the decision-making process.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications.

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.